<DOC>
	<DOCNO>NCT00105326</DOCNO>
	<brief_summary>The primary objective study evaluate amelioration sleep architecture patient schizophrenia schizophrenia-related insomnia , treat either 9 mg extended-release paliperidone ER placebo , use polysomnography .</brief_summary>
	<brief_title>Trial Evaluating Paliperidone Extended-Release ( ER ) Tablets Versus Placebo Sleep Schizophrenia Patients</brief_title>
	<detailed_description>Paliperidone major active substance produce metabolism risperidone body . In patient schizophrenia , risperidone show improve quality sleep . Therefore possible treatment paliperidone may improve sleep quality potentially quality life patient . The goal study test hypothesis paliperidone improve sleep architecture . This trial multicenter , double-blind ( neither patient physician know placebo drug give dose ) , randomize ( patient assign different treatment group base solely chance ) , placebo-controlled study patient schizophrenia schizophrenia relate insomnia . The study consist 2 phase : screen phase 14 day double-blind phase 15 day . The primary purpose study evaluate improvement sleep architecture patient schizophrenia schizophrenia-related insomnia , treat either 9 mg/day paliperidone ER placebo 14 day , use polysomnography . In study , polysomnography ( polygraphic record sleep multiple body function related state stage sleep ass possible biological cause sleep disorder ) use measure sleep architecture continuity . Measurements take 2 day screen phase ( average baseline value ) last 2 day treatment phase ( averaged end point value ) include measurement non-rapid eye movement ( NREM ) sleep ( include 4 stage sleep ) measure rapid eye movement ( REM ) sleep . Other assessment pertinent continuity efficiency sleep sleep latency ( length time take go full wakefulness Stage 2 sleep ) , sleep efficiency ( proportion sleep time bed ) , sleep maintenance ( period time sleep onset awaken number awakening ) , sleep duration ( total sleep time ) also measure . At baseline , Day 7 , end treatment , Positive Negative Syndrome Scale ( PANSS ) use ass symptom schizophrenia Clinical Global Impression Scale - Severity ( CGI-S ) use assess severity patient condition . Safety assessment include incidence adverse event throughout study ; daily measurement vital sign ( blood pressure , pulse , temperature ) ; clinical laboratory test perform study initiation end treatment ; measurement extrapyramidal symptom use scale ( EPS scale ) baseline , Day 7 end point . 9 mg paliperidone ER placebo take orally daily Days 1 14</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Diagnosed schizophrenia schizophreniarelated insomnia , relapse psychosis least 3 month screen , consider symptomatically stable apnea/hypopnea score &lt; 10 periodic leg movement score arousal index &lt; 10 Weigh &gt; /= 50 kg ( &gt; /=110 lb ) , BMI &gt; /= 18 &lt; /= 35 kg/m2 , inclusive Agree adhere sleep schedule Have sleep history minimum 1.5 hour wakefulness 8 hour bed . Current history suicidal violent behavior exhibit behavior within past 6 month diagnosis primary insomnia unstable blood pressure sleep problem related general medical condition , substance abuse diagnosis evidence narcolepsy preexist severe gastrointestinal narrowing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenia-related insomnia</keyword>
	<keyword>insomnia</keyword>
	<keyword>paliperidone</keyword>
	<keyword>placebo</keyword>
	<keyword>polysomnography</keyword>
</DOC>